Mirum Pharmaceuticals, Inc. (MIRM) FY2026 Q2 Statement of Cash Flows

Statement of Cash Flows

2026-04-01 to 2026-06-30

Swipe to see the full flow
Mirum Pharmaceuticals, Inc. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Proceeds from issuance of convertible notes, net of issuance costs → financing reconciliation: $672,435,000.00Proceeds from issuance of common stock pursuant to equity plans → financing reconciliation: $13,368,000.00financing reconciliation → Net cash from financing activities: $211,438,000.00financing reconciliation → Exchange and repurchase of 2029 convertible notes: $474,365,000.00Proceeds from maturities of investments → investing reconciliation: $25,847,000.00investing reconciliation → Purchase of investments: $160,815,000.00investing reconciliation → Payments made for additions to intangible assets: $25,000,000.00investing reconciliation → Purchase of property and equipment: $23,000.00Net cash used in operating activities → operating reconciliation: $44,252,000.00Stock-based compensation → operating reconciliation: $30,573,000.00Change in fair value of holdback liabilities → operating reconciliation: $12,158,000.00Debt conversion inducement expense → operating reconciliation: $11,678,000.00Depreciation and amortization → operating reconciliation: $6,936,000.00Unrealized foreign exchange loss (gain) → operating reconciliation: $896,000.00Amortization of debt discount and offering costs → operating reconciliation: $658,000.00Non-cash lease expense → operating reconciliation: $595,000.00Inventory → operating reconciliation: $395,000.00operating reconciliation → Net loss: $67,227,000.00operating reconciliation → Accounts payable, accrued expenses and other liabilities: $19,061,000.00operating reconciliation → Accounts receivable: $13,744,000.00operating reconciliation → Other assets: $5,835,000.00operating reconciliation → Prepaid and other current assets: $1,084,000.00operating reconciliation → Operating lease liabilities: $630,000.00operating reconciliation → Other: $299,000.00operating reconciliation → Holdback liabilities: $261,000.00Net cash used in investing activities → investing reconciliation: $159,991,000.00Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations → Cash sources and uses: $326,640,000.00Net cash from financing activities → Cash sources and uses: $211,438,000.00Cash sources and uses → Exchange-rate effect: $1,373,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $332,462,000.00Cash sources and uses → Net cash used in investing activities: $159,991,000.00Cash sources and uses → Net cash used in operating activities: $44,252,000.00Net loss: -$67,227,000.00Net loss−$67.23 MStock-based compensation: $30,573,000.00Stock-based compensation+$30.57 MDepreciation and amortization: $6,936,000.00Depreciation & amortization+$6.94 MAmortization of debt discount and offering costs: $658,000.00Debt cost amortization+$658.00 KUnrealized foreign exchange loss (gain): $896,000.00Unrealized FX gain & loss+$896.00 KNon-cash lease expense: $595,000.00Non-cash lease expense+$595.00 KInventory reserves and firm commitment losses: $0.00Fair value of common stock issued in connection with asset acquisition: $0.00Debt conversion inducement expense: $11,678,000.00Conversion inducement expense+$11.68 MChange in fair value of holdback liabilities: $12,158,000.00Holdback liability fair value+$12.16 MOther: -$299,000.00Other non-cash items−$299.00 KAccounts receivable: -$13,744,000.00Accounts receivable−$13.74 MPrepaid and other current assets: -$1,084,000.00Prepaid & other assets−$1.08 MInventory: $395,000.00Inventories+$395.00 KOther assets: -$5,835,000.00Other operating assets−$5.84 MAccounts payable, accrued expenses and other liabilities: -$19,061,000.00Payables, accrued & other−$19.06 MHoldback liabilities: -$261,000.00Holdback liabilities−$261.00 KOperating lease liabilities: -$630,000.00Operating lease liabilities−$630.00 KNet cash used in operating activities: -$44,252,000.00. Cash required to fund net payments.Operating cash−$44.25 Moperating reconciliation: $108,141,000.00Proceeds from issuance of convertible notes, net of issuance costs: $672,435,000.00Debt issued, net of costs+$672.44 MExchange and repurchase of 2029 convertible notes: -$474,365,000.00Convertible debt repaid−$474.37 MProceeds from issuance of common stock and pre-funded warrants in private placement, net of issuance costs: $0.00Proceeds from issuance of common stock pursuant to equity plans: $13,368,000.00Employee stock plans & options+$13.37 MNet cash from financing activities: $211,438,000.00Financing cash+$211.44 Mfinancing reconciliation: $685,803,000.00Purchase of investments: -$160,815,000.00Investment purchases−$160.82 MProceeds from maturities of investments: $25,847,000.00AFS securities maturities+$25.85 MPurchase of property and equipment: -$23,000.00PP&E purchases−$23.00 KPayments made for additions to intangible assets: -$25,000,000.00Intangible asset purchases−$25.00 MNet cash used in investing activities: -$159,991,000.00. Cash required to fund net payments.Investing cash−$159.99 Minvesting reconciliation: $185,838,000.00Cash sources and uses: $538,078,000.00Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $326,640,000.00Beginning cash$326.64 MEnding cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $332,462,000.00Ending cash$332.46 MExchange-rate effect: -$1,373,000.00FX effect−$1.37 MCASH RECONCILIATIONFinancingflowsInvestingflowsOperatingflowsNet loss −$67.23M + net operating adjustments $22.98M = operating cash −$44.25MFree cash flow−$44.28 MOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change+$5.82 MEnding cash − beginning cash
Chart details

Mirum Pharmaceuticals, Inc. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026

Cash flows for Apr 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations. Beginning cash: Mar 31, 2026. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Mar 31, 2026
326,640,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
Operating activities
negative 44,252,000 US dollars. Net cash used.
Net loss
negative 67,227,000 US dollars
Stock-based compensation
30,573,000 US dollars
Depreciation and amortization
6,936,000 US dollars
Amortization of debt discount and offering costs
658,000 US dollars
Unrealized foreign exchange loss (gain)
896,000 US dollars
Non-cash lease expense
595,000 US dollars
Inventory reserves and firm commitment losses
0 US dollars
Fair value of common stock issued in connection with asset acquisition
0 US dollars
Debt conversion inducement expense
11,678,000 US dollars
Change in fair value of holdback liabilities
12,158,000 US dollars
Other
negative 299,000 US dollars
Accounts receivable
negative 13,744,000 US dollars
Prepaid and other current assets
negative 1,084,000 US dollars
Inventory
395,000 US dollars
Other assets
negative 5,835,000 US dollars
Accounts payable, accrued expenses and other liabilities
negative 19,061,000 US dollars
Holdback liabilities
negative 261,000 US dollars
Operating lease liabilities
negative 630,000 US dollars
Investing activities
negative 159,991,000 US dollars. Net cash used.
Purchase of investments
negative 160,815,000 US dollars
Proceeds from maturities of investments
25,847,000 US dollars
Purchase of property and equipment
negative 23,000 US dollars
Payments made for additions to intangible assets
negative 25,000,000 US dollars
Financing activities
211,438,000 US dollars. Net cash provided.
Proceeds from issuance of convertible notes, net of issuance costs
672,435,000 US dollars
Exchange and repurchase of 2029 convertible notes
negative 474,365,000 US dollars
Proceeds from issuance of common stock and pre-funded warrants in private placement, net of issuance costs
0 US dollars
Proceeds from issuance of common stock pursuant to equity plans
13,368,000 US dollars
Operating adjustment reconciliation
108,141,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
685,803,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
185,838,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
negative 1,373,000 US dollars
Ending cash on Jun 30, 2026
332,462,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
Cash sources and uses
538,078,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
5,822,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
negative 44,252,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
23,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
negative 44,275,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$67.23M + net operating adjustments $22.98M = operating cash −$44.25M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: negative 44,252,000 US dollars minus 23,000 US dollars equals negative 44,275,000 US dollars.
Mirum Pharmaceuticals, Inc. (MIRM) FY2026 Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!